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PredilationAbstract Introduction: Several studies have demonstrated that percutaneous coronary interven-
tion (PCI) induces the release of multiple inﬂammatory markers which is associated with a later
poor prognosis. We aimed to evaluate the inﬂammatory response to PCI via the assessment of
the pre- and post-PCI serum levels of high-sensitive C-reactive protein (hsCRP), interleukin
(IL)-6, and intercellular adhesion molecule (ICAM)-1 in relation to the technique of stenting
(predilation versus direct stenting [DS]), the type of stent (bare-metal [BMS] versus drug-eluting
stents [DES]), the various coronary lesion characteristics, and the other PCI procedural variables.
Methods: We studied 75 consecutive patients (aged 54.2 ± 9.1 years, 54 men) enrolled between
March and September 2012. BMS and DES were deployed in 46 and 29 patients respectively; via
predilation technique in 37 patients and DS technique in 38 patients. Patients were evaluated
monthly in the cardiology outpatient clinic for 6 months.
Results: The procedural increase in hsCRP and ICAM-1 was statistically signiﬁcant in high risk
coronary lesions (total occlusions, bifurcation lesions, and in-stent restenosis). The PCI-induced
change of mean hsCRP, IL-6, and ICAM-1 levels was statistically signiﬁcant in relation to the
technique of stenting (predilation leads to augmented inﬂammatory response compared to DS)
but was unrelated to the type of stent (BMS or DES).
Conclusions: Predilation signiﬁcantly augments the inﬂammatory response to PCI than DS
irrespective of the type of stent (BMS or DES). So, if predilation is required before any type of stent,
measures to improve the patient’s inﬂammatory proﬁle should be carried out in advance.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Several studies have demonstrated that percutaneous coronary
intervention (PCI) induces the release of multiple inﬂammato-
ry markers1–3 which is associated with poor prognosis4 and
might interfere with the clinical outcome when surgical or
38 S.A. Sakr et al.medical treatments are subsequently required.5 In humans,
coronary stents have been shown to elicit an initial acute
inﬂammatory cell response within 0–3 days, centered at the
stent struts.5 The stimulus for the inﬂammatory process is
the disruption of the coronary endothelial layer with a subse-
quent prompt activation of the inﬂammatory cells, with early
neutrophil recruitment to the site of injury, followed by pro-
longed macrophage accumulation.6
In this study, we aimed to evaluate the inﬂammatory
response to PCI via the assessment of the pre- and post-PCI
serum levels of high-sensitive C-reactive protein (hsCRP),
interleukin (IL)-6, and intercellular adhesion molecule
(ICAM)-1 in relation to the technique of stenting (predilation
versus direct stenting [DS]), the type of stent (bare-metal
[BMS] versus drug-eluting stents [DES]), the various lesion
characteristics, and the other PCI procedural variables.
2. Patients and methods
2.1. Patient selection
We studied 75 consecutive patients enrolled between March
and September 2012 from Medicine Specialized Hospital
(Mansoura University, Egypt). Patients who underwent coro-
nary stenting in our institution were included in the study
unless they met at least one of the following exclusion criteria:
left ventricular (LV) ejection fraction <30%, severe heart fail-
ure, cardiogenic shock, signiﬁcant renal impairment (serum
creatinine >2 mg/dl), clinical evidence of acute inﬂammation,
malignancy, pregnancy, rheumatic conditions, hepatic decom-
pensation, and treatment with steroids or immunosuppressive
drugs.
2.2. Deﬁnitions of variables
Hypercholesterolemia was deﬁned as serum total cholesterol
(TC) > 200 mg/dl or treatment with lipid-lowering drugs, dia-
betes as fasting blood glucose level >126 mg/dl on more than
2 occasions or treatment with insulin or oral hypoglycemic
drug(s), and hypertension as blood pressure P140/90 mm Hg
on more than 2 occasions or current treatment with antihyper-
tensive drug(s). Current smoking was deﬁned as actively con-
suming P1 cigarette/day on the time of admission or in the
past year.
Major adverse cardiac events (MACE) were deﬁned as the
occurrence of death, acute coronary syndromes (unstable
angina or myocardial infarction [MI]), or the need for coro-
nary revascularization (via PCI or coronary artery bypass
grafting [CABG] surgery) within a follow-up period of
6 months. In this context, unstable angina was deﬁned as
angina pectoris (or equivalent type of ischemic discomfort)
with at least one of the following features: (1) occurring at rest
(or on minimal exertion) and usually lasting >20 min (if not
interrupted by the administration of a nitrate or an analgesic);
(2) being severe and usually described as frank pain; or (3)
occurring with a crescendo pattern (i.e., pain that awakens
the patient from sleep or that is more severe, prolonged, or fre-
quent than previously). Acute, evolving, or recent MI was
diagnosed by typical rise and/or fall of biochemical markers
of myocardial necrosis with at least one of these criteria: (1)
ischemic symptoms; (2) development of pathologic Q-wavesin the ECG; (3) ECG changes indicative of ischemia
(ST-segment elevation or depression); (4) imaging evidence
of new loss of viable myocardium or new regional wall motion
abnormality.
2.3. Coronary intervention and sample acquisition
After local anesthesia, a sheath was placed into the femoral
artery for insertion of coronary angiography and angioplasty
catheters. All patients were pre-medicated with diazepam.
Before intracoronary manipulations, an intravenous heparin
bolus (80 IU/kg) was administered. A non-ionic contrast medi-
um (Omnipaque, Nycomed Imaging, AS) was used in all
processes.
The type of coronary stent, the need for predilation, and
ﬁnal balloon size for stent deployment were chosen by the
operators to obtain an angiographic residual stenosis close to
zero%. All patients were given aspirin 300 mg and clopidogrel
300 mg before angioplasty.
The PCI procedure was considered successful when the fol-
lowing criteria were fulﬁlled: (1) post-procedural stenosis
<10% in the worst of 2 orthogonal views with normal con-
trast run-off in the stented artery, (2) no vascular complica-
tions during the procedure, (3) no clinical complications
within 48 h after the procedure, and (4) no signiﬁcant increase
in the markers of myocardial necrosis (creatine kinase-MB and
troponin-I) 24 and 48 h after the procedure.
After the procedure, the arterial sheath was manually
removed when the activated clotting time was <150 s without
the use of vascular closure devices; and the patients continued
to receive 75 mg/day of aspirin indeﬁnitely and 75 mg/day of
clopidogrel for 12 months for DES (6 months for patients with
BMS).
Blood samples were obtained within 1 h before and 24 h
following PCI after 12 h overnight fasting. The inﬂammatory
response to PCI was deﬁned as the difference between baseline
and post-procedural levels of the studied inﬂammatory marker
(calculated as the serum level of the inﬂammatory marker after
the procedure minus its level before the procedure).
2.4. Clinical and angiographic assessment
For follow-up and recording of clinical events, patients were
required to visit the cardiac outpatient clinic monthly after
the procedure, or when any anginal symptoms occurred. On
each visit, the patients were examined clinically, with the addi-
tion of a simple exercise test when recommended.
Event-free survival was deﬁned as freedom from MACE.
Patients with symptoms or ﬁndings suggestive of myocardial
ischemia underwent follow-up angiograms. In-segment angio-
graphic restenosis was deﬁned as the loss of >50% of the ini-
tial gain achieved with PCI anywhere within the stent or within
the 5-mm borders proximal or distal to the stent.7
2.5. Laboratory assessment
Fasting venous blood samples (5 ml each) were obtained from
all patients before and 24 h after PCI, and their sera were stored
at70 C until later assessment for hsCRP, IL-6, and ICAM-1.
Serum levels of ICAM-1 were determined by Enzyme
Linked Immuno-sorbent Assay (ELISA) kits obtained from
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GA 30092, USA). Serum IL-6 levels were measured by Boster
Immune Leader Kit (Boster Biological Technology Ltd.,
Fremont, CA 94538, USA). Quantitative determination of
serum hsCRP was done by immuno-turbidimetric method
(Unimate 3 CP, Roche Milan, Italy). The normal upper refer-
ence value for hsCRP using this method is 5 mg/L.
Serum fasting glucose level, liver functions, serum creati-
nine, blood urea nitrogen, and serum electrolytes (sodium,
potassium, chloride, and bicarbonates) were measured by
automated auto-analyzer (Cobas Integra, Roche, Germany).
Full blood count was analyzed by automated cell counter
(Sysmex, Roche, Germany). Fasting lipid proﬁle elements (to-
tal cholesterol [TC], high-density lipoprotein cholesterol
[HDL-C], and triglycerides [TG]) were measured by the stan-
dard enzymatic methods; while low-density lipoprotein choles-
terol (LDL-C) was estimated by using Friedewald equation
(LDL-C = TC – HDL-C – TG/5).
2.6. Statistical methods
Results are represented as mean ± SD for continuous variables
and as percentages for non-continuous data. Comparison of
percentages was carried out by using v2 test. Comparisons of
means of continuous data across a grouping variable with 2
or more levels were performed using student’s ‘‘t’’ and one-
way analysis of variance (ANOVA) tests, respectively. A 2-
tailed p-value <0.05 was considered statistically signiﬁcant.
All analyses were performed using the SPSS statistical software
for Windows, version 21 (SPSS Inc., Chicago, Illinois, USA).
2.7. Ethical statement
The study protocol conforms to the declaration of Helsinki,
and was approved by our institutional ethical committee.
Written informed consent was obtained from all patients prior
to their inclusion in the study.3. Results
This study included 75 patients, 54 (72%) males and 21 (28%)
females, aged of 54.2 ± 9.1 years. Table 1 shows the elements
of the inﬂammatory response to PCI, expressed as the
difference between pre- and post-PCI levels of high-sensitive
C-reactive protein (hsCRP), interleukin (IL)-6, and intercellu-
lar adhesion molecule (ICAM)-1, studied in relation to differ-
ent sets of variables.
3.1. Demographic/history variables
Hypertension was found in 41 patients (54.7%) while 29
(38.7%) were diabetics (13 with type I and 16 with type II),
28 (37%) current smokers, 40 (53%) dyslipidemia, and 32
(42.7%) had positive family history of coronary artery disease
(CAD). The patients were maintained on statins (n= 62
patients, 83%), aspirin (n= 71, 95%), clopidogrel (n= 58,
77%), beta-blockers (n= 39, 52%), and angiotensin-convert-
ing enzyme inhibitors (ACEIs)/angiotensin-receptor blockers
(ARBs) (n= 43, 57%). There were no statistically signiﬁcant
differences in the magnitude of inﬂammatory response toPCI (in terms of the 3 studied inﬂammatory markers) in rela-
tion to these demographic/clinical variables (p> 0.05 for all
comparisons; Table 1).
3.2. Clinical variables
The majority of patients (n= 34; 45.3%) presented with stable
angina, 29 (38.7%) presented with unstable angina (UA)/non-
ST-elevation MI (NSTEMI) and 12 (16%) patients presented
with STEMI. Thirty patients (40%) had New York Heart
Association (NYHA) class-I dyspnea; and only 5 patients
(6.7%) had NYHA class-IV dyspnea. There were no statisti-
cally signiﬁcant differences in the magnitude of inﬂammatory
response to PCI in relation to these clinical variables
(p> 0.05 for all comparisons; Table 1).
3.3. ECG and Echo variables
Only 8 patients (11%) had normal ECG ﬁndings; 30 (40%)
had ST-T wave change, and 37 (49%) had pathologic Q-waves.
On Echo examination, 27 patients (36%) had diastolic LV dys-
function (21 patients with grade-I and 6 patients with grade-II
and higher). There were no statistically signiﬁcant differences
in the magnitude of inﬂammatory response to PCI in relation
to these ECG or Echo variables (p> 0.05 for all comparisons;
Table 1).
3.4. Coronary lesion variables
Ostial lesions existed in 15 patients (20%); while 12 patients
(16%) suffered chronic total occlusions, 33 patients (44%)
had bifurcation lesions, and in-stent restenosis was found in
11 patients (14.7%). The majority of coronary lesions belonged
to type B1 (n= 35; 46.7%), while the least prevalent was type C
(n= 7; 9.3%); types A and B2 existed in 19 (25.3%) and 14
(18.7%) patients respectively. TIMI-3 ﬂow was observed in
47 patients (62.7%), TIMI-2 in 10 patients (13.3%), TIMI-1
in 6 patients (8%), and TIMI-0 in 12 patients only (16%).
Table 1 demonstrates a statistically signiﬁcant increase in
the magnitude of inﬂammatory response to PCI (shown by
the higher hsCRP and ICAM-1 difference) in patients with
chronic total occlusion, bifurcation lesion, and in-stent
restenosis. Characteristically, mean IL-6 difference was sig-
niﬁcantly increased in patients with in-stent restenosis in
response to PCI.
3.5. Prognostic variables
A total of 9 MACE occurred in 6 patients (8%) over a follow-
up period of 6 months. The events included 1 case with sudden
death, 2 cases with MI (one of them as re-infarction), 1 case
underwent CABG, and 5 cases underwent revascularization
with PCI. There were no statistically signiﬁcant differences in
the magnitude of inﬂammatory response to PCI in relation
to MACE (p> 0.05 for all comparisons; Table 1).
3.6. Technique of stenting and type of stent
BMSs were deployed in 46 patients (61.3%); only balloon-ex-
pandable, stainless steel, tubular, thin-strut stents with
Table 1 The elements of the inﬂammatory response to PCI, expressed as the mean difference between pre- and post-PCI levels of
high-sensitive C-reactive protein (hsCRP), interleukin (IL)-6, and intercellular adhesion molecule (ICAM)-1, studied in relation to the
different sets of variables (using one-way ANOVA and t-tests).
Variables hsCRP diﬀerence IL-6 diﬀerence ICAM-1 diﬀerence
Mean ± SD p-Value Mean ± SD p-Value Mean ± SD p-Value
Demographic/history variables
Gender
Male (n= 54) 1.72 ± 0.49 0.734 1.75 ± 0.45 0.098 2.15 ± 0.47 0.192
Female (n= 21) 1.68 ± 0.35 1.55 ± 0.50 2.30 ± 0.36
Hypertension
Present (n= 41) 1.68 ± 0.37 0.509 1.86 ± 0.46 0.123 2.13 ± 0.45 0.179
Absent (n= 34) 1.75 ± 0.54 1.69 ± 0.48 2.27 ± 0.44
Diabetes mellitus
None (n= 46) 1.50 ± 0.33 0.531 1.65 ± 0.55 0.729 1.97 ± 0.39 0.176
Type I (n= 13) 1.55 ± 0.36 1.57 ± 0.63 2.24 ± 0.51
Type II (n= 16) 1.69 ± 0.47 1.66 ± 0.67 2.29 ± 0.46
Smoking
None (n= 32) 1.63 ± 0.34 0.380 1.17 ± 0.65 0.123 2.20 ± 0.37 0.976
Current (n= 28) 1.78 ± 0.58 2.10 ± 0.48 2.19 ± 0.55
Ex-smoker (n= 15) 1.77 ± 0.36 1.67 ± 0.51 2.20 ± 0.41
Dyslipidemia
Present (n= 40) 1.70 ± 0.39 0.277 1.78 ± 0.46 0.206 2.29 ± 0.44 0.223
Absent (n= 35) 1.59 ± 0.48 1.64 ± 0.49 2.17 ± 0.40
CAD family history
Present (n= 32) 1.72 ± 0.41 0.329 1.62 ± 0.45 0.466 2.27 ± 0.45 0.216
Absent (n= 43) 1.63 ± 0.38 1.70 ± 0.48 2.14 ± 0.44
Pharmacotherapy
Statins
Present (n= 62) 1.64 ± 0.44 0.292 1.59 ± 0.49 0.599 2.14 ± 0.47 0.943
Absent (n= 13) 1.78 ± 0.39 1.67 ± 0.53 2.13 ± 0.36
Aspirin
Present (n= 71) 1.61 ± 0.40 0.708 1.65 ± 0.38 0.534 2.09 ± 0.42 0.238
Absent (n= 4) 1.69 ± 0.66 1.78 ± 0.79 2.37 ± 0.99
Clopidogrel
Present (n= 58) 1.59 ± 0.37 0.417 1.62 ± 0.57 0.244 2.13 ± 0.38 0.446
Absent (n= 17) 1.68 ± 0.49 1.83 ± 0.87 2.22 ± 0.56
Beta-blockers
Present (n= 39) 1.75 ± 0.46 0.848 1.74 ± 0.53 0.359 2.17 ± 0.77 0.167
Absent (n= 36) 1.77 ± 0.43 1.63 ± 0.50 2.38 ± 0.49
ACEIs/ARBs
Present (n= 43) 1.71 ± 0.59 0.873 1.69 ± 0.47 0.304 2.27 ± 0.56 0.518
Absent (n= 32) 1.69 ± 0.45 1.57 ± 0.53 2.19 ± 0.48
Clinical variables
Clinical presentation
Stable angina (n= 34) 1.57 ± 0.63 0.532 1.54 ± 0.55 0.799 2.09 ± 0.39 0.445
UA/NSTEMI < 1 week (n= 29) 1.71 ± 0.40 1.82 ± 0.45 2.25 ± 0.41
STEMI < 1 week (n= 12) 1.79 ± 0.36 1.76 ± 0.38 2.19 ± 0.51
NYHA class
I (n= 30) 1.75 ± 0.47 0.310 1.83 ± 0.39 0.662 2.22 ± 0.36 0.417
II (n= 22) 1.69 ± 0.35 1.98 ± 0.37 2.16 ± 0.42
III (n= 18) 1.76 ± 0.31 1.39 ± 0.43 2.44 ± 0.52
IV (n= 5) 1.35 ± 0.41 1.32 ± 0.45 2.09 ± 0.48
ECG variables
Normal ECG (n= 8) 1.67 ± 0.34 0.212 1.13 ± 0.69 0.495 2.07 ± 0.37 0.226
ST-T wave changes (n= 30) 1.83 ± 0.58 1.93 ± 0.71 2.09 ± 0.29
Q-waves (n= 37) 1.63 ± 0.36 1.71 ± 0.61 2.21 ± 0.46
Echo variables
LV diastolic dysfunction
Normal (n= 48) 1.64 ± 0.38 0.428 1.81 ± 0.73 0.634 1.98 ± 0.46 0.592
Grade-I (n= 21) 1.80 ± 0.60 2.10 ± 0.58 2.18 ± 0.37
Grade-II and higher (n= 6) 1.73 ± 0.62 1.91 ± 0.62 2.24 ± 0.29
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Table 1 (continued)
Variables hsCRP diﬀerence IL-6 diﬀerence ICAM-1 diﬀerence
Mean ± SD p-Value Mean ± SD p-Value Mean ± SD p-Value
Coronary lesion variables
Ostial lesion
Present (n= 15) 1.58 ± 0.68 0.364 1.58 ± 0.61 0.852 2.17 ± 0.49 0.880
Absent (n= 60) 1.77 ± 0.73 1.61 ± 0.54 2.15 ± 0.45
Total occlusion
Present (n= 12) 1.84 ± 0.54 <0.001** 1.74 ± 0.56 0.421 2.53 ± 0.52 0.023*
Absent (n= 63) 1.18 ± 0.61 1.59 ± 0.73 2.18 ± 0.47
Bifurcation lesion
Present (n= 33) 1.84 ± 0.70 0.021* 1.75 ± 0.54 0.578 2.36 ± 0.53 0.007**
Absent (n= 42) 1.47 ± 0.69 1.69 ± 0.39 2.06 ± 0.41
In-stent restenosis
Present (n= 11) 2.00 ± 0.55 0.014* 1.93 ± 0.48 0.002** 2.48 ± 0.40 0.006**
Absent (n= 64) 1.66 ± 0.39 1.53 ± 0.37 2.07 ± 0.45
Coronary thrombus
Present (n= 13) 1.68 ± 0.57 0.284 1.76 ± 0.56 0.402 2.10 ± 0.50 0.388
Absent (n= 62) 1.47 ± 0.65 1.57 ± 0.77 2.23 ± 0.44
Lesion type
A (n= 19) 1.22 ± 0.71 0.312 1.69 ± 0.57 0.465 1.97 ± 0.36 0.611
B1 (n= 35) 1.45 ± 0.70 1.79 ± 0.36 2.05 ± 0.44
B2 (n= 14) 1.56 ± 0.63 1.68 ± 0.49 2.00 ± 0.39
C (n= 7) 1.52 ± 0.66 1.86 ± 0.46 2.08 ± 0.45
TIMI ﬂow grade
0 (n= 12) 1.83 ± 0.65 0.930 1.85 ± 0.60 0.879 2.19 ± 0.80 0.648
1 (n= 6) 1.73 ± 0.36 1.63 ± 0.75 2.15 ± 0.73
2 (n= 10) 1.68 ± 0.49 1.76 ± 0.68 2.31 ± 0.53
3 (n= 47) 1.86 ± 0.46 1.81 ± 0.54 2.02 ± 0.47
Prognostic variables
MACE at 6 months
Present (n= 6) 1.79 ± 0.51 0.298 1.55 ± 0.47 0.591 2.25 ± 0.43 0.391
Absent (n= 69) 1.62 ± 0.37 1.44 ± 0.59 2.33 ± 0.61
Abbreviations: ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin-receptor blockers; CAD: coronary artery disease; ECG:
electrocardiogram/electrocardiographic; Echo: echocardiography/echocardiographic; hsCRP: high-sensitive C-reactive protein; IL: interleukin;
ICAM: intercellular adhesion molecule; LV: left ventricle/ventricular; MACE: major adverse cardiac events; NSTEMI: non-ST elevation
myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; pts: patients; STEMI: ST elevation
myocardial infarction; TIMI: thrombolysis in acute myocardial infarction; UA: unstable angina.
* p< 0.05.
** p< 0.01.
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Endeavor and Nobori types). In this study, 37 patients
(49%) were treated with predilation before stenting and 38
patients (51%) with DS.
Table 2 shows the interaction between the stenting tech-
niques (predilation and DS) and types of stents (BMS and
DES); and the resultant impact of this interaction on the
inﬂammatory response to PCI. As shown in the table, there
was a statistically signiﬁcant difference in the magnitude of
inﬂammatory response to PCI in relation to the technique of
stenting but not the type of stent; where predilation resulted
in an augmented inﬂammatory response to PCI compared to
DS whether BMS or DES were deployed.
4. Discussion
Histological studies have shown that PCI induces a sig-
niﬁcant inﬂammatory reaction in the vascular wall with local
increases in biochemical markers, leukocyte inﬁltration, and
neointimal hyperplasia.8,9 The current study showed thatthe PCI-induced release of hsCRP and ICAM-1 was more
pronounced in high risk/complex coronary lesions.
Moreover, The PCI-induced increase of mean hsCRP, IL-6,
and ICAM-1 levels was not related to the type of stent
(BMS or DES) but was rather related to the technique of
stenting; where predilation resulted in augmented inﬂamma-
tory response to PCI compared to DS.
4.1. ICAM-1 as an element of the inﬂammatory response to PCI
Soluble forms of adhesion molecules (such as sICAM-1, sP-
selectin and sE-selectin) have been the aim of several previous
studies. The presence of high ICAM-1 values has been commu-
nicated in patients with CAD,10 acute MI11,12 and UA.13
Soluble ICAM-1 levels were consistently elevated in patients
with acute MI after attempted reperfusion by balloon angio-
plasty compared with controls and thrombolysed patients.14
Clinically, signiﬁcantly elevated soluble ICAM-1 levels were
found after PTCA14 and in the coronary sinus 2 min after
PCI, but not in peripheral blood.11
Table 2 High-sensitive C-reactive protein (hsCRP), interleukin (IL)-6, and intercellular adhesion molecule (ICAM)-1 in relation to
the interaction between stenting techniques and stent types.
Variables hsCRP diﬀerence IL-6 diﬀerence ICAM-1 diﬀerence
BMS DES p-Value BMS DES p-Value BMS DES p-Value
Predilation (n = 25) (n = 12) 0.877 (n = 25) (n = 12) 0.118 (n = 25) (n = 12) 0.281
1.88 ± 0.25 1.89 ± 0.32 2.15 ± 0.15 2.06 ± 0.18 2.38 ± 0.50 2.56 ± 0.39
Direct stenting (n = 21) (n = 17) 0.562 (n = 21) (n = 17) 0.714 (n = 21) (n = 17) 0.396
1.68 ± 0.38 1.61 ± 0.41 1.86 ± 0.19 1.88 ± 0.13 2.11 ± 0.34 2.22 ± 0.45
p-Value 0.037* 0.048* <0.001** 0.004** 0.042* 0.044*
Abbreviations as in Table 1.
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technique
In this study, predilation was associated with statistically sig-
niﬁcant increase in the mean peri-procedural change of the
inﬂammatory markers (CRP, IL6, and ICAM-1) compared
to DS, denoting a more intense inﬂammatory response with
predilation. This result agrees with the ﬁndings of Li et al.15
where SES implantation using DS signiﬁcantly attenuated
the early systemic inﬂammatory response in patients with sin-
gle-vessel disease compared with predilation (plasma CRP and
IL-6 levels were higher in predilation than in DS group at 24
and 72 h post-stenting). Our study is considered as extension
to that of Li et al., as we obtained similar results but with
the use of both BMS and DES.
Also, Brasselet et al.16 showed that the total duration of
inﬂation was related to CRP levels when predilation is used,
whereas inﬂation pressure was not. In contrast, the maximum
and average inﬂation pressures were related to CRP level when
DS was used, whereas inﬂation duration was not. While the
study of Brasselet et al. focused only on hsCRP, our study
showed that 3 important inﬂammatory markers (ICAM-1,
IL6, and hsCRP) were signiﬁcantly increased with predilation
than with DS.
4.3. The inﬂammatory response to PCI in relation to the type of
stent
The comparative induction of inﬂammatory response after
BMS and DES deployment has been currently evaluated,
where the peri-PCI changes of mean hsCRP, IL-6 and
ICAM-1 levels were not statistically signiﬁcant between both
types of stents. It was documented that stent type did not inﬂu-
ence the change in CRP level, even after adjusting for clinical
and anatomic differences observed between groups,17 in agree-
ment with our ﬁndings.
In their randomized trial, Dibra et al.18 performed serial
measurements of hsCRP in the patients who received SES
and in those with BMS, and they reported that the median val-
ues of hsCRP before and after stenting were similar between
both groups, with no statistically signiﬁcant difference.18 In
another study, a blunted inﬂammatory response to PCI in
terms of reduced CRP peri-procedure ratio was found in sub-
jects with ACS implanted with SES compared to BMS recipi-
ents. Karha et al. demonstrated that the increase of hsCRP
after PCI was smaller in patients implanted with SES than in
those with BMS in a large cohort of patients.19Variability in the magnitude of acute-phase response may
be due to a different degree of stent-induced vessel injury
and to a different susceptibility to inﬂammatory stimuli (some
patients exhibit hyper-responsiveness to pro-inﬂammatory
damage compared to others). All these considerations might
explain the variability and un-predictable inﬂammatory
response elicited by stenting.2
The early inﬂammatory response to PCI was also present
after DES deployment which releases substances possessing
anti-proliferative and anti-inﬂammatory activities; indicating
the lack of an inhibitory effect of these drugs on the local
release of inﬂammatory mediators in the early post-stenting
phase.20 The effect of these drugs (sirolimus and paclitaxel),
although released shortly after stent deployment, is likely to
be unable to counteract the endothelial response following
the resultant trauma from stent deployment.20 The acute
post-procedural systemic inﬂammatory response induced by
DES appears to be similar to that induced by BMS7,17,20 in
accordance with our results.
4.4. Clinical implications
Our results may indicate that predilation signiﬁcantly increases
the coronary inﬂammation than DS, irrespective of the type of
stent used. Such augmented inﬂammatory response has been
proved to be associated with no-reﬂow, early and late stent
thrombosis and re-stenosis. Thus, if predilation is required
before either type of stent (BMS or DES), measures to improve
the patient’s coronary inﬂammatory proﬁle should be carried
out in advance. Such measures may include the use of high-
dose statins,21 thienopyridines,22 and glycoprotein IIb/IIIa
receptor antagonists.23
In an experimental study, liposomes with nitrogen-contain-
ing bisphosphonates were administered, which enter the mono-
cytes or macrophages, and then undergo lipolysis with the
release of anti-hyperplastic agents preventing cell activation.24
This approach will be evaluated clinically and may inhibit the
cellular proliferation in patients with predominant inﬂamma-
tory component.
4.5. Limitations
The main limitation of the study is a rather small sample size,
and the high prevalence of males is another issue. Also, the
enrollment rate in this study is about 3 patients per week;
which may denote selection bias. In fact, the weekly rate of
coronary interventions in our institute is about 10–12 cases
Stenting technique and the inﬂammatory response to PCI 43(divided on 4 days; one day for each team); and we should
declare that our team is allowed to include only the cases
scheduled in their speciﬁed duty day.
As the study is not randomized, there is a potential bias in
patients’ selection for DS versus predilation technique.
However, we should conﬁrm here that the decision to use
predilation or DS was largely dependent on the characteristics
of the lesion itself and not on the operator’s personal
preference.
5. Conclusions
From our results, we may conclude that predilation signiﬁcant-
ly augments the inﬂammatory response to PCI than DS irre-
spective of the type of stent (BMS or DES). So, if
predilation is required before any type of stent, measures to
improve the patient’s inﬂammatory proﬁle should be carried
out in advance.
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